Počet záznamov: 1

bortezomib

SYS		d000069286
LBL		00000nz--a2200181n--4500
005		20250606221744.4
008		160101\|\|\|anznnbabn-----------\|-a\|a------
040		$b slo $a BA006 $d BA006
065		$a D01.029.260.110.500
065		$a D01.132.285.500
065		$a D02.203.200.500
065		$a D03.383.679.450
066		$a 01 $c 03
150		$a bortezomib $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo
450		$w v $a LDP-341 $2 slo
450		$w v $a PS 341 $2 slo
550		$7 sllk_us_auth*d000970 $Y Antineoplastic Agents $w P $a antineoplastiká
665		$a 2016 (2000) $2 eng
680	9-	$i A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. $2 eng
750	-2	$a Bortezomib $2 eng
980		$x M

Počet záznamov: 1